{"id":"NCT00975130","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","officialTitle":"An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Na√Øve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-08","completion":"2012-02","firstPosted":"2009-09-11","resultsPosted":"2012-12-07","lastUpdate":"2017-04-13"},"enrollment":3366,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"BIOLOGICAL","name":"SC golimumab","otherNames":["SCH 900259, subcutaneous"]},{"type":"BIOLOGICAL","name":"IV golimumab","otherNames":["SCH 900259, intravenous"]}],"arms":[{"label":"SC-GLM50","type":"EXPERIMENTAL"},{"label":"IV GLM 2 mg/kg + GLM50-SC","type":"EXPERIMENTAL"},{"label":"GLM50-SC","type":"EXPERIMENTAL"}],"summary":"Part 1 of this trial will assess the safety and effectiveness of subcutaneous (SC) golimumab administered by autoinjector once monthly, when combined with different disease-modifying antirheumatic drug (DMARD) regimens used in daily rheumatology practice. Subsequently, Part 2 will study if a strategy of intravenous (IV) golimumab to induce remission followed by SC golimumab to retain remission is superior to continuing a SC regimen.","primaryOutcome":{"measure":"Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6","timeFrame":"Month 6","effectByArm":[{"arm":"GLM50-SC","deltaMin":2692,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23740226","28431485","25664404","24839031"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":203,"n":3357},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}